Enhanced Implantable Cellular and Biotherapeutic Agent Delivery Canister

An implantable device for delivering cellular and biotherapeutic agents with improved nanophase tubular structure, enhancing agent release and diffusion exchange.

The original patent's implantable cellular and biotherapeutic agent delivery canister has limitations in terms of agent release and diffusion exchange. The new inventive concept addresses these limitations by incorporating a porous metal canister with a controlled nanophase tubular structure, enhancing metabolically active agent release and facilitating fluid and diffusion exchange.

The new inventive concept comprises a system for delivering cellular and biotherapeutic agents, featuring a porous metal canister with a nanophase tubular structure having a controlled thickness of 50-100 microns. This structure is integrated with a substrate to facilitate fluid and diffusion exchange to the agents. The canister is designed with a bicontinuous morphology to enhance metabolically active agent release. Additionally, the device includes a rigid, through-porous membrane integrated with a metallic capsule, and a nanophase tubular structure having a diameter of 50-500 nm to facilitate agent release. The system enables a controlled and efficient release of agents, improving treatment outcomes.

The new inventive concept introduces a controlled nanophase tubular structure with a specific thickness range, a bicontinuous morphology, and a rigid, through-porous membrane, which are not present in the original patent. These features provide an enhanced and more efficient delivery of cellular and biotherapeutic agents.

Alternative embodiments of the inventive concept could include varying the nanophase tubular structure's thickness, diameter, and material composition to optimize agent release and diffusion exchange. Additionally, the device could be adapted for use in different disease conditions or with various types of agents.

The enhanced implantable cellular and biotherapeutic agent delivery canister has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the treatment of chronic and costly disease conditions. The device could be marketed as a more efficient and effective alternative to traditional pharmaceutical-based therapies.